Business · 27/12/2024

FDA Modifies Labeling of Buprenorphine-Containing Transmucosal Products for Opioid Dependence Treatment

The US Food and Drug Administration (FDA) is updating the labeling of buprenorphine-containing transmucosal products to address concerns that certain statements may be misinterpreted as establishing a maximum dosage, potentially limiting patients' access to these medications for opioid dependence treatment.